S. 1040 · 119th Congress · Health
Drug Competition Enhancement Act
Prohibits drug manufacturers from product hopping and authorizes the Federal Trade Commission to enforce this prohibition. AI-read
- IntroducedMar 13, 2025 Done
- CommitteeReported Apr 10, 2025 Done
- Senate floorAwaiting vote Current stage
- House floorNot yet Not reached yet
- Chambers agreeNot yet Not reached yet
- PresidentNot yet Not reached yet
What it does
This bill prohibits product hopping by drug manufacturers and authorizes the Federal Trade Commission (FTC) to enforce this prohibition.
Generally, product hopping describes a situation where, when the patents on a reference drug (or biological product) expire, the manufacturer switches to a follow-on product that is covered by a later-expiring patent. Under this bill, a follow-on product is a modified version of the reference drug that has an indication (what the drug is used for) that is identical or substantively similar to an indication of the reference drug.
The bill establishes a presumption that product hopping has occurred when a reference drug manufacturer, after receiving notice that the Food and Drug Administration has received an application to market a competing generic (or biosimilar) version, takes certain actions such as withdrawing the reference drug from the market and selling a follow-on product.
A drug manufacturer may rebut these presumptions by demonstrating that its conduct was not intended to limit competition.
The bill makes product hopping an unfair method of competition and provides for enforcement by the FTC. If the FTC has reason to believe a manufacturer has violated or is about to violate this prohibition on product hopping, the FTC may institute an administrative proceeding or bring suit in federal court to stop the manufacturer’s action and seek equitable remedies, including disgorgement of unjust profits or paying restitution to those harmed.
Congressional Research Service · summary of “Introduced in Senate” version · Mar 13, 2025
Who lobbies on it
18 organizations · 127 filings · Q1 2025–Q3 2026One square per quarter since introduction, oldest left. Filled = named it that quarter.
-
Pharmaceutical Research and Manufacturers of America
7 of 7 quarters
“Issues related to competition pracitces in the pharmaceutical marketplace. S.1040 - Drug Competition Enhancement Act. S.1041 - Affordable Prescriptions for Patients Act. S.2658 - Medication Affordability and Patent Integrity Act (MAPIA). S.1095 - Stop STALLING Act. S.43 - Skinny Labels, Big Savings Act.”
-
America's Health Insurance Plans Inc (ahip)
7 of 7 quarters
“H.R. 1 - One Big Beautiful Bill Act - Rep. Arrington, Jodey - Medicaid eligibility and state financing, Marketplace coverage and enrollment, Health Savings Account expansion, Pharmacy Benefit Manager financing and regulation H.R. 843 - Prompt Approval of Safe Generic Drugs Act - Rep. Barragan, Nanette Diaz - Generic…”
-
Pfizer, Inc.
7 of 7 quarters
“Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041, Affordable Prescriptions for Patients Act.”
15 more organizations, every filingPROUpgrade
Organizations that named S. 1040 in a quarterly lobbying report. Covers organizations with a PAC on file; reports from organizations without one aren’t loaded yet. Spend is the organization’s total across all issues: reports don’t split spending by bill. Source: Senate lobbying disclosures (LD-2) from lda.gov; quotes are word for word from the “specific lobbying issues” field.
Actions
5 actions · newest first- Apr 10, 2025Placed on Senate Legislative Calendar under General Orders. Calendar No. 43.
- Apr 10, 2025Committee on the Judiciary. Reported by Senator Grassley with an amendment. Without written report.
- Apr 3, 2025Committee on the Judiciary. Ordered to be reported with an amendment favorably.
- Mar 13, 2025Read twice and referred to the Committee on the Judiciary.
Show all 5 actionsShow fewer
- Mar 13, 2025Introduced in Senate
What members said about it
-
Senate Judiciary Committee Advances Six Bipartisan Bills To Lower Prescription Drug Prices
This morning, the U.S. Senate Judiciary Committee advanced six bipartisan bills to help lower the price of prescription drugs.
“Families are struggling to afford their medications. Congress must take an all-options approach to lowering prescription drug prices, and the bills we advanced today embody that spirit. The legislative package will improve coordination between agencies, bring generic drugs to market more quickly, and foster competition…”